EGFR+ Lung Cancer

Ravi Salgia, MD, explains how treatment with a tyrosine kinase inhibitor in patients with non–small cell lung cancer can lead to disease transformation.

In a subgroup analysis of patients with non-small cell lung cancer who have EGFR sensitizing mutations, the regimen of atezolizumab plus bevacizumab plus carboplatin, and paclitaxel, had a stonger survival benefit compared to other therapies.

During a live virtual event, Matthew A. Gubens, MD, MS, discussed adjuvant chemotherapy using carboplatin or cisplatin in patients with EGFR-positive non–small cell lung cancer.

The addition of bevacizumab to erlotinib did not demonstrated improvement in overall survival in patients with EGFR-mutant non–small cell lung cancer treated in a phase 3 study.

During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, and participants discussed the challenges of molecular testing and how to use test results to introduce targeted treatments for patients with non–small cell lung cancer.

DZD9008 for the treatment of patients with locally advanced or metastatic non–small cell lung cancer harboring with EGFR exon20 insertion mutations is an investigative treatment strategy in a clinical trial.

Megan May, PharmD, discusses fitting newer targeted therapies into the treatment paradigm for EGFR exon 20 insertion mutation-positive non–small cell lung cancer.

Danny Nguyen, MD, discusses an analysis of efficacy and adverse events of mobocertinib in patients with EGFR-positive non–small cell lung cancer that was presented at the European Society for Medical Oncology 2021 Congress.

Results from the phase 2 OCEAN trial show that osimertinib is effective in treating central nervous system metastases from non–small cell lung cancer in patients with certain mutations.

Telisotuzumab vedotin has shown interim efficacy in patients with advanced or metastatic EGFR wild-type non–small cell lung cancer and has now been granted breakthrough therapy designation from the FDA

Patritumab deruxtecan has been granted a breakthrough therapy designation by the FDA to accelerate its development for the treatment of patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer with disease progression on or after treatment with a third-generation tyrosine kinase inhibitor and platinum-based therapies.

In patients with EGFR-positive non–small cell lung cancer who develop a T790M mutation after disease progression, chemo-antiangiogenesis may prove beneficial.

Tegavivint is being tested in combination with osimertinib in an effort to prolong overall survival and deepen response in EGFR+ NSCLC.

The Ocomine Dx Target Test is now FDA-approved to help identify eligible patients to be treated with amivantamab.

The application for poziotinib is supported by the phase 2 ZENITH20 trial. The agent showed a promising safety profile and antitumor activity.

Alexander Spira, MD, PhD, FACP, discusses the prognosis of patients with EGFR- exon 20 mutated non-small cell lung cancer.

Compared with chemotherapy alone combination of sintilimab (Tyvyt) plus a bevacizumab biosimilar injection and chemotherapy significantly improves progression-free survival in EGFR NSCLC.

During a Targeted Oncology Case-Based Roundtable event, Mark A. Socinski, MD, led a discussion about treatment of patients with EGFR-mutant non–small cell lung cancer.

Neoadjuvant osimertinib may lead to a better mechanistic understanding of what drives incomplete response and residual disease for patients with EGFR-mutant NSCLC. according to Collin M. Blakely, MD, PhD.

Findings from the phase 1/2 trial of mobocertinib show clinical activity in a subset of patients with EGFR exon 20-positive non–small cell lung cancer.

In combination with chemotherapy and sintilimab, a bevacizumab biosimilar injection was found to increase PFS in patients with Nonsquamous NSCLC who progressed after a prior EGFR-TKI.

Although osimertinib has been shown to overcome T790M-mediated mutations in the second-line setting, as with other EGFR tyrosine kinase inhibiors progression on osimertinib is inevitable.

Phase 2 study results signal benefit of neoadjuvant osimertinib in patients with surgically resectable EGFR-mutant non–small cell lung cancer.

Osimertinib (Tagrisso) plus bevacizumab does not produce a superior progression-free survival (PFS) benefit over osimertinib monotherapy in patients with non-squamous non-small cell lung cancer harboring an EGFR mutation. However, for patients who have a history of smoking or an exon 20 deletion, the combination may prove beneficial.

Results from a phase 1/2 study showed a high rate of objective response with mobocertinib in a subset of patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer.

During a Targeted Oncology Case-Based Roundtable event, Miguel Albino, MD, of Texas Oncology, discussed the case of a 73-year-old patient with EGFR-mutant non–small cell lung cancer.

The combination of plinabulin with docetaxel showed improvement in overall survival compared with docetaxel alone as treatment of patients with second- and third-line non –small cell lung cancer with EGFR wild type, meeting the primary end point of the phase 3 DUBLIN-3 clinical trial.

Research shows that methods used to treat the wide epidermal growth factor receptor-positive population are often not successful for patients with specific biomarkers like EGFR exon 20 insertion mutations, highlighting an ongoing need for more targeted therapies.

Nathan Pennell, MD, PhD, discusses the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer.